Benoxaprofen

Summary

Benoxaprofen (CHEMBL340978) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M01AE06); indicated across 1 condition including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M01AE06
• Indications: 1 condition
• Chemistry: 301.72 Da · C16H12ClNO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL340978
Name	Benoxaprofen
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	39941
ChEBI	CHEBI:76114
ATC	M01AE06
Molecular formula	C16H12ClNO3
Molecular weight	301.72
InChIKey	MITFXPHMIHQXPI-UHFFFAOYSA-N

SMILES: CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O

IUPAC name: 2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid

ChEBI definition: A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor, antipyretic, non-narcotic analgesic, protein kinase C agonist, hepatotoxic agent, antipsoriatic, nephrotoxic agent.

Also known as: Benoxaprofen, Benoxaprofene, Benoxaprofeno, COMPD 90459, COMPOUND 90459, COMPOUND-90459, Coxigon, NSC-299582, Opren, Oraflex, benoxaprofen, (R,S)-Benoxprofen

Patent coverage: 4,531 distinct patent families (17,569 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 17,287 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Amine oxidase [flavin-containing] A, Bile salt export pump, Alpha-1A adrenergic receptor.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).